Should I buy or sell Aerovate Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVTE shares. View AVTE analyst ratings or view top-rated stocks .

What is Aerovate Therapeutics' stock price target for 2024?

3 equities research analysts have issued 12 month target prices for Aerovate Therapeutics' shares. Their AVTE share price targets range from $35.00 to $65.00. On average, they anticipate the company's stock price to reach $49.33 in the next year. This suggests a possible upside of 122.6% from the stock's current price. View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts .

How have AVTE shares performed in 2024?

Aerovate Therapeutics' stock was trading at $22.63 on January 1st, 2024. Since then, AVTE stock has decreased by 2.1% and is now trading at $22.16. View the best growth stocks for 2024 here .

Are investors shorting Aerovate Therapeutics?

Aerovate Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 993,100 shares, an increase of 9.9% from the March 15th total of 903,700 shares. Based on an average daily trading volume, of 130,200 shares, the short-interest ratio is presently 7.6 days. Currently, 5.8% of the company's stock are sold short. View Aerovate Therapeutics' Short Interest .

When is Aerovate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our AVTE earnings forecast .

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its quarterly earnings results on Sunday, November, 14th. The company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26).

When did Aerovate Therapeutics IPO?

Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free AVTE Stock Alerts

$22.00

+0.40 (+1.85%)

(As of 02:50 PM ET)

Compare

Today's Range: $20.73
▼
$22.41
50-Day Range: $18.80
▼
$30.75
52-Week Range: $9.41
▼
$32.42

Volume: 144,324 shs
Average Volume: 129,540 shs
Market Capitalization: $612.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $49.33

Get Aerovate Therapeutics alerts:

Aerovate Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 122.6% Upside
$49.33 Price Target
Short Interest: Bearish
5.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.70
Based on 10 Articles This Week
Insider Trading: Selling Shares
$2.03 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.78) to ($2.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.56 out of 5 stars

Medical Sector

661st out of 918 stocks

Pharmaceutical Preparations Industry

296th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Aerovate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aerovate Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.78% of the float of Aerovate Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aerovate Therapeutics has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Aerovate Therapeutics has recently increased by 9.89%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aerovate Therapeutics does not currently pay a dividend.
Dividend Growth
Aerovate Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVTE.

3.7

News and Social Media Coverage

News Sentiment
Aerovate Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Aerovate Therapeutics this week, compared to 1 article on an average week.
Search Interest
9 people have searched for AVTE on MarketBeat in the last 30 days.
MarketBeat Follows
4 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aerovate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,033,870.00 in company stock.
Percentage Held by Insiders
19.30% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aerovate Therapeutics are expected to decrease in the coming year, from ($2.78) to ($2.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aerovate Therapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aerovate Therapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aerovate Therapeutics has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Aerovate Therapeutics Stock (NASDAQ:AVTE)

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

AVTE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVTE Stock News Headlines

April 19, 2024 | insidertrades.com

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Sells $247,000.00 in Stock

April 13, 2024 | insidertrades.com

Insider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 7,500 Shares of Stock

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 12, 2024 | insidertrades.com

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Director Sells $334,478.30 in Stock

April 4, 2024 | insidertrades.com

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 3,325 Shares

March 29, 2024 | insidertrades.com

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Benjamin T. Dake Sells 11,068 Shares

March 28, 2024 | insidertrades.com

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 3,432 Shares

March 21, 2024 | insidertrades.com

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $138,224.00 in Stock

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 17, 2024 | americanbankingnews.com

Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Grows By 9.9%

April 14, 2024 | americanbankingnews.com

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $201,375.00 in Stock

April 13, 2024 | americanbankingnews.com

David S. Grayzel Sells 11,882 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Stock

April 13, 2024 | americanbankingnews.com

Aerovate Therapeutics (NASDAQ:AVTE) Shares Down 5.4% After Insider Selling

April 12, 2024 | americanbankingnews.com

Aerovate Therapeutics (NASDAQ:AVTE) Shares Gap Down to $28.05

April 4, 2024 | finance.yahoo.com

Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares

April 2, 2024 | markets.businessinsider.com

Aerovate Therapeutics: Poised for Market Capitalization Growth on IMPAHCT Trial Success

April 1, 2024 | msn.com

Aerovate Therapeutics (NASDAQ:AVTE) on the Verge of Substantial Growth

March 27, 2024 | globenewswire.com

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

March 27, 2024 | finance.yahoo.com

Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023

March 26, 2024 | finanznachrichten.de

Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

March 26, 2024 | markets.businessinsider.com

Aerovate Therapeutics: A Strong Buy Ahead of Key Clinical Data Release

March 25, 2024 | benzinga.com

Recap: Aerovate Therapeutics Q4 Earnings

March 25, 2024 | investorplace.com

AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023

March 25, 2024 | markets.businessinsider.com

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

March 25, 2024 | globenewswire.com

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

March 24, 2024 | morningstar.com

Aerovate Therapeutics Inc AVTE

March 21, 2024 | finance.yahoo.com

Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...

See More Headlines

Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AVTE
CUSIP: N/A
CIK: 1798749
Web: aerovatetx.com
Phone: 617-443-2400
Fax: N/A
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $49.33
High Stock Price Target: $65.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +128.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-75,520,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -61.62%
Return on Assets: -55.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.04
Quick Ratio: 7.04

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.96 per share
Price / Book: 5.45

Miscellaneous

Outstanding Shares: 27,860,000
Free Float: 22,483,000
Market Cap: $601.78 million
Optionable: Not Optionable
Beta: 1.23

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Timothy P. Noyes M.B.A. (Age 62)
CEO & Director
Comp: $703.8k
Mr. George A. Eldridge (Age 61)
CFO & Treasurer
Comp: $533.89k
Dr. Marinus Verwijs Ph.D. (Age 48)
Chief Technical Officer
Comp: $439.88k
Dr. Benjamin T. Dake Ph.D. (Age 48)
Founder, President, COO & Secretary
Comp: $435.5k
Dr. Ralph W. Niven M.B.A. (Age 64)
M.R, Ph.D., Pharm.S, Chief Scientific Officer
Comp: $372.33k
Mr. Hunter Gillies M.D. (Age 58)
Chief Medical Officer
Comp: $512.74k
Mr. Timothy J. Pigot (Age 53)
Chief Commercial Officer
Ms. Donna Dea
Head of Regulatory Affairs
Ms. Susan Fischer
Executive Vice President of Development Operations
Mr. Stephen K. Yu
Senior Vice President of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aerovate Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aerovate Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVTE shares.
View AVTE analyst ratings or view top-rated stocks.
What is Aerovate Therapeutics' stock price target for 2024?: 3 equities research analysts have issued 12 month target prices for Aerovate Therapeutics' shares. Their AVTE share price targets range from $35.00 to $65.00. On average, they anticipate the company's stock price to reach $49.33 in the next year. This suggests a possible upside of 122.6% from the stock's current price.
View analysts price targets for AVTE or view top-rated stocks among Wall Street analysts.
How have AVTE shares performed in 2024?: Aerovate Therapeutics' stock was trading at $22.63 on January 1st, 2024. Since then, AVTE stock has decreased by 2.1% and is now trading at $22.16.
View the best growth stocks for 2024 here.
Are investors shorting Aerovate Therapeutics?: Aerovate Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 993,100 shares, an increase of 9.9% from the March 15th total of 903,700 shares. Based on an average daily trading volume, of 130,200 shares, the short-interest ratio is presently 7.6 days. Currently, 5.8% of the company's stock are sold short.
View Aerovate Therapeutics' Short Interest.

When is Aerovate Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our AVTE earnings forecast.
How were Aerovate Therapeutics' earnings last quarter?: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its quarterly earnings results on Sunday, November, 14th. The company reported ($0.26) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.26).
When did Aerovate Therapeutics IPO?: Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share.
How do I buy shares of Aerovate Therapeutics?: Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVTE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial